Description ⋅ May 25, 2019 6:51 PM RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA). (SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe. It is the number one genetic cause of death for infants. According to a company filling, price tag for treatment is $2.1 million. Product is called Zolgensma @VolatilityWatch Disclaimer : I currently do not own any position in RGNX. This is not advice to buy or sell, It is for educational purposes. Please do your homework before investing.